Breast Cancer Coverage from Every Angle

Matteo Lambertini, MD, PhD, on Atezolizumab in Triple-Negative Breast Cancer

Posted: Monday, July 15, 2019

Now that an atezolizumab-containing regimen has been approved for eligible patients with advanced triple-negative breast cancer, what are some of the investigational approaches being explored with this agent in earlier-stage disease?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.